The American Journal of Surgery
Volume 194, Issue 2 , Pages 172-175 , August 2007

Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients

  • Cathal J. Moran, F.R.C.S.I.

      Affiliations

    • Department of Surgery, National Breast Screening Program, Eccles Unit, University College Dublin, 36 Eccles St, Dublin 7, Ireland
    • ,
  • Malcolm R. Kell, M.D., F.R.C.S.I.

      Affiliations

    • Department of Surgery, National Breast Screening Program, Eccles Unit, University College Dublin, 36 Eccles St, Dublin 7, Ireland
    • Corresponding Author InformationCorresponding author. Tel.: +353-1-882-6200; fax: +353-1-882-6225.
    • ,
  • Fidelma L. Flanagan, M.D., F.R.C.R.

      Affiliations

    • Department of Radiology, National Breast Cancer Screening Program, Eccles Unit, University College Dublin, Mater Misericordiae University Hospital, 36 Eccles St, Dublin 7, Ireland
    • ,
  • Maria Kennedy, M.R.C.Path

      Affiliations

    • Department of Pathology, National Breast Cancer Screening Program, Eccles Unit, University College Dublin, Mater Misericordiae University Hospital, 36 Eccles St, Dublin 7, Ireland
    • ,
  • Thomas F. Gorey, M.Ch., F.R.C.S.I.

      Affiliations

    • Department of Surgery, National Breast Screening Program, Eccles Unit, University College Dublin, 36 Eccles St, Dublin 7, Ireland
    • ,
  • Michael J. Kerin, M.Ch., F.R.C.S.I.

      Affiliations

    • Department of Surgery, National Breast Screening Program, Eccles Unit, University College Dublin, 36 Eccles St, Dublin 7, Ireland

Received 11 April 2006 ,Revised 7 November 2007

References 

  1. Lagios MD. Duct carcinoma in situ: biological implications for clinical practice Semin Oncol. 1996;1(suppl 2):6–11
  2. Silverstein MJ. Ductal carcinoma in situ of the breast: a surgeon’s disease. Ann Surg Oncol. 1999;6:802–810
  3. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004;96:906–920
  4. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7–33
  5. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol. 1994;11:167–180
  6. Noguchi M. Current controversies concerning sentinel lymph node biopsy for breast cancer. Breast Cancer Res Treat. 2004;84:261–271
  7. Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS?. Am Surg. 2001;67:513–518
  8. Silverstein MJ. Ductal carcinoma of the breast. BMJ. 1998;317:734–739
  9. Kelly TA, Kim JA, Patrick R, et al. Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ. Am J Surg. 2003;186:368–370
  10. Pendas S, Dauway E, Giuliano R, et al. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol. 2000;7:15–20
  11. Cserni G. Sentinel lymph node biopsy as a tool for the staging of ductal carcinoma in situ in patients with breast carcinoma. Surg Today. 2002;32:99–103
  12. Adamovich TL, Simons RM. Ductal carcinoma in situ with microinvasion. Am J Surg. 2003;186:112–116
  13. Cox CE, Pendas S, Cox JM, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg. 1998;227:645–653
  14. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathological validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997;226:271–276
  15. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996;276:1818–1822
  16. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394–399
  17. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet. 1997;349:1864–1867
  18. Giuliano AE, Jones RC, Brennan M, Statman RR. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997;15:2345–2350
  19. Kell MR, Kerin MJ. Sentinel lymph node biopsy. BMJ. 2004;328:1330–1331
  20. Lagios MD, Silverstein MJ. Sentinel node biopsy for patients with DCIS: a dangerous and unwarranted direction. Ann Surg Oncol. 2001;8:275–277
  21. Silverstein MJ, Gierson ED, Colburn WJ, et al. Axillary lymphadenectomy for intraductal carcinoma of the breast. Surg Gynecol Obstet. 1991;172:211–214
  22. Silverstein MJ, Barth A, Poller DN, et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma of the breast. Eur J Cancer. 1995;31:1425–1427
  23. Silverstein MJ, Barth A, Poller DN, et al. A prognostic Index for ductal carcinoma of the breast. Lancet. 1995;345:1154–1157
  24. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996;77:2267–2274
  25. Tabar L, Chen HH, Duffy SW. A novel method for prediction of long term outcome of women with T1a, T1b and 10-14mm of invasive breast cancer: a prospective study. Lancet. 2000;355:429–433
  26. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–398
  27. Guenther JM, Krishnamoorthy M, Tan LR. Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am. 1997;3:336–340
  28. Offidile R, Hoh C, Barsky SH, et al. Minimally invasive breast carcinoma staging using lymphatic mapping with radiolabelled dextran. Cancer. 1998;82:1704–1708
  29. Reuhl T, Kaisers H, Markwardt J, Haensch W, Hohenberger P, Schlag PM. Axillary node removal in clinical node-negative breast carcinoma (Can its indication be individualized by “sentinel node” detection?). Dtsch Med Wochenschr. 1998;123:583–587
  30. Peley G, Sinkovics I, Liszkay G, et al. The role of intra-operative gamma-probe guided sentinel lymph node biopsy in the treatment of malignant melanoma and breast cancer (Hungarian). Orv Hetil. 1999;140:2331–2338
  31. Imoto S, Hasebe T. Initial experience with sentinel node biopsy in breast cancer at the National Cancer Centre Hospital East. Jpn J Clin Oncol. 1999;29:11–15
  32. Klauber de More N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy—is it indicated in patients with DCIS and patients with micro-invasion?. Ann Surg Oncol. 2000;7:636–642
  33. Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg. 2003;138:309–313
  34. Lee CH, Carter D, Philpotts SE, et al. Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted?. Radiology. 2000;217:466–470
  35. Schwartz GF, Patchefsky AS, Finklestein SD, et al. Nonpalpable in situ ductal carcinoma of the breast (Predictors of multicentricity and microinvasion and implications for treatment). Arch Surg. 1989;124:29–32
  36. Chung MA, Wazer D, Cady B. Contemporary management of breast cancer. Obstet Gynecol Clin North Am. 2002;29:173–188
  37. Lara JF, Young SM, Velilla RE, et al. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer. 2003;98:2105–2113
  38. Jakub JW, Cox CE, Pippas AW, Gardner M, Pendas S, Reintgen DS. Controversial topics in breast lymphatic mapping. Semin Oncol. 2004;31:324–332
  39. Cody HS, Klauber DeMore N, Borgen PI, et al. Is it really duct carinoma in situ?. Ann Surg Oncol. 2001;8:617–619
  40. Dowlatshahi K, Fan M, Snider HC. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer. 1997;80:1188–1197
  41. Cote RJ, Peterson HF, Chaiwun B International Breast Cancer Study Group. Role of immunohistochemical detection of lymph node metastases in management of breast cancer. Lancet. 1999;354:896–900
  42. Diel IJ, Kaufmann M, Costa SD. Micrometastic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst. 1996;88:1652–1664
  43. Braun S, Pantel K, Muller P. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med. 2000;342:525–533
  44. Mullenix PS, Cuadrado DG, Steele SR, et al. Secondary operations are frequently required to complete the surgical phase of therapy in the era of breast conservation and sentinel lymph node biopsy. Am J Surg. 2004;187:643–646
  45. Arnaud S. Patients and surgeons perspectives on axillary surgery for breast cancer. Eur J Surg Oncol. 2004;30:735–743
  46. Gemignani ML, Cody HS, Fey JV, et al. Impact of sentinel lymph node mapping on related charges in patients with early-stage breast cancer. Ann Surg Oncol. 2000;7:575–580
  47. Rutgers EJ. Sentinel node procedure in breast carcinoma: a valid tool to omit unnecessary axillary treatment or even more?. Eur J Cancer. 2004;40:182–186
  48. Fuhrman GM. Sentinel lymph node mapping and biopsy for ductal carcinoma in situ and other controversial indications. Am Surg. 2004;70:403–406
  49. Farkas EA, Stolier AJ, Teng SC, et al. An argument against routine sentinel node mapping for DCIS. Am Surg. 2004;70:13–17

PII: S0002-9610(07)00307-8

doi: 10.1016/j.amjsurg.2006.11.027

The American Journal of Surgery
Volume 194, Issue 2 , Pages 172-175 , August 2007

Article Tools